Standard
The Expanding Therapeutic Horizon and Emerging Clinical Risks of GLP-1 Receptor Agonists
The medical community is witnessing a paradigm shift in the application of glucagon-like peptide-1 receptor agonists (GLP-1RAs), as these once-specialized diabetes medications evolve into multi-faceted tools for treating obesity, substance use disorders, and behavioral addictions. While the rapid expansion of GLP-1RAs—marketed under names such as Ozempic, Wegovy, and Mounjaro—has been hailed as a breakthrough in…
